APA (7th ed.) Citation

Kexun Zhou, Pei Shu, Hanrui Zheng, & Qiu Li. (2023). Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Kexun Zhou, Pei Shu, Hanrui Zheng, and Qiu Li. Cost-effectiveness Analysis of Toripalimab Plus Chemotherapy as the First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Without EGFR or ALK Driver Mutations from the Chinese Perspective. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Kexun Zhou, et al. Cost-effectiveness Analysis of Toripalimab Plus Chemotherapy as the First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Without EGFR or ALK Driver Mutations from the Chinese Perspective. Frontiers Media S.A., 2023.